Reimbursement for several wound care products cut

Rehab Regs, April 6, 2007

Following a late 2006 U.S. Food and Drug Administration ruling, CMS will no longer pay for several wound care products, including Xenaderm Ointment, reported Medicare & Reimbursement Advisor Weekly. Therapists use Xenaderm as a topical treatment to promote the healing of decubitus/pressure ulcers.

Therapists said that despite the product's high cost, it saved time in the healing process and had positive clinical outcomes, which saved money over time. Additional wound care products no longer receiving Medicare reimbursement include BCT-Allenderm-T, trypsin complex, Optase Gel, Granulex, and Granulderm & TBC, reported Medicare & Reimbursement Advisor Weekly.

Most Popular